title: [Reduction of vascular pain due to drop-infusion of oxaliplatin (L-OHP) in peripheral vein with heated infusion route].
abstract: OBJECTIVE
  The aim of this study is to investigate the possibility of reducting vascular pain with peripheral vein administration of oxaliplatin (L-OHP)by heating infusion routes during XELOX therapy.
  
  
  METHODS
  (1) EXPERIMENT: The temperature of the 5%glucose injection solution was measured at the leading edge of the infusion route when it was heated to 36°Cor 40°C. (2) CASES: Among five patients receving XELOX therapy for colorectal cancer, we examined the occurrence of vascular pain by heating the L-OHP solution to 40°C.
  
  
  RESULTS
  (1) EXPERIMENT: The injection temperatures were reduced to 25°C and 31°C while passing through the infusion route when L-OHP solution was heated to 36°C and 40°C, respectively. (2) CASE: vascular pain did not occur in all five patients treated with XELOX therapy completely by heating the L-OHP solution at 40°C, including two patients who could not continue treatment caused by vascular pain without the heating method.
  
  
  CONCLUSIONS
  The method using the heat infusion route of L-OHP at 40°C is useful for reducing vascular pain from L-OHP administered intravenously.
authors.affiliation: Dept. of Nursing, Health Insurance Hitoyoshi General Hospital.
authors.forename: Masaaki
authors.initials: M
authors.lastname: Yatate
authors.forename: Masami
authors.initials: M
authors.lastname: Kimura
authors.forename: Yuri
authors.initials: Y
authors.lastname: Iwasaki
authors.forename: Motoki
authors.initials: M
authors.lastname: Kamura
authors.forename: Megumi
authors.initials: M
authors.lastname: Yokoi
authors.forename: Shoko
authors.initials: S
authors.lastname: Uchitani
authors.forename: Takao
authors.initials: T
authors.lastname: Mizumoto
authors.forename: Hiroo
authors.initials: H
authors.lastname: Matsushita
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D000069287:Capecitabine; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D006358:Hot Temperature; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000077150:Oxaliplatin; D010071:Oxaloacetates; D010146:Pain / Q000139:chemically induced / Q000517:prevention & control*
chemical_list: D009944:Organoplatinum Compounds; D010071:Oxaloacetates; D000077150:Oxaliplatin; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil